down arrow

Tasly Pharmaceutical Group Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000001C81
  • SHG: 600535
CNY
13.95
-0.12 (-0.85%)

Sep 22

SHG

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Tasly Pharmaceutical Group Co., Ltd.

Why is Tasly Pharmaceutical Group Co., Ltd. ?

1
With ROE of 7.63%, it has a very attractive valuation with a 1.55 Price to Book Value
  • Over the past year, while the stock has generated a return of -9.98%, its profits have fallen by -1%
  • At the current price, the company has a high dividend yield of 2.4
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Tasly Pharmaceutical Group Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Tasly Pharmaceutical Group Co., Ltd. for you?

Low Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Tasly Pharmaceutical Group Co., Ltd.
-11.2%
0.12
21.06%
China Shanghai Composite
3.23%
0.23
14.72%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-6.02%
EBIT Growth (5y)
1.96%
EBIT to Interest (avg)
26.04
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.59
Tax Ratio
18.31%
Dividend Payout Ratio
41.91%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
10.65%
ROE (avg)
10.17%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.55
EV to EBIT
13.53
EV to EBITDA
10.77
EV to Capital Employed
1.61
EV to Sales
2.22
PEG Ratio
NA
Dividend Yield
2.35%
ROCE (Latest)
11.90%
ROE (Latest)
7.63%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company
ROCE(HY)

Highest at 9.61%

INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

RAW MATERIAL COST(Y)

Fallen by 0.23% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -25.76 %

OPERATING PROFIT(Q)

Highest at CNY 695.82 MM

OPERATING PROFIT MARGIN(Q)

Highest at 34.17 %

PRE-TAX PROFIT(Q)

Highest at CNY 626.59 MM

NET PROFIT(Q)

Highest at CNY 545.63 MM

EPS(Q)

Highest at CNY 0.35

-6What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at CNY 1,941.67 MM

INTEREST(Q)

At CNY 4.16 MM has Grown at 25%

Here's what is working for Tasly Pharmaceutical Group Co., Ltd.

Operating Profit
Highest at CNY 695.82 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Operating Profit Margin
Highest at 34.17 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at CNY 626.59 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Pre-Tax Profit
At CNY 626.59 MM has Grown at 67.23%
over average net sales of the previous four periods of CNY 374.68 MM
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit
Highest at CNY 545.63 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

Net Profit
At CNY 545.63 MM has Grown at 109.69%
over average net sales of the previous four periods of CNY 260.2 MM
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS
Highest at CNY 0.35
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Debt-Equity Ratio
Lowest at -25.76 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by 0.23% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
At CNY 115.13 MM has Grown at inf%
period on period (QoQ)
MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (CNY MM)

Here's what is not working for Tasly Pharmaceutical Group Co., Ltd.

Operating Cash Flow
Lowest at CNY 1,941.67 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest
At CNY 4.16 MM has Grown at 25%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Footer loading